DemandAnnouncement
ConcertAI's Cara AI engine and TriaLinQ identify eligible cancer trial patients roughly 3x faster than manual methods
Built on NVIDIA AI, the tools assess eligibility across the CancerLinQ network of nearly 1,000 sites of care and over 13 million patient records. ConcertAI's systems support up to 50% higher trial enrollment.
- Source
- Nvidia news post, published Nov 13, 2026
- Published here
This fact was extracted from the source above and checked automatically: every number and company named here appears in it. When the same fact turns up in another filing or post, that source is added here instead of a second copy. Read the original before relying on it.